Effect of Magnesium Sulphate in Mothers suffering from Toxemia of Pregnancy and their Neonates

Faith R Lulalire, Peter N Karimi, Evans M Mwagangi, George Wandolo

Abstract


Background: Severe pre-eclampsia is one of the major causes of high maternal mortality rate in both developed and developing countries. The goals of management are to prevent progression to eclampsia thus preventing convulsions, to control the blood pressure and to prevent untoward effects in the foetus. The first-line option for the treatment and prevention of eclamptic seizures is magnesium sulphate.

Objective: To determine the serum magnesium, urea and electrolyte levels in neonates of mothers treated with magnesium sulphate and compare the findings with the levels in non-exposed neonates.

Methodology: A quasi experimental design was adopted where test subjects were neonates of mothers suffering from preeclampsia and severe eclampsia and were being treated with magnesium sulphate just before delivery at Pumwani Maternity hospital. The control group comprised neonates of hypertensive mothers without preeclampsia being treated using other drugs. Blood samples were obtained from the mother at onset of labor and from the neonates at birth and analyzed in the clinical chemistry laboratory of the University of Nairobi.

Results:  A total of 54 mothers and their neonates were enrolled with 27 in each arm of the study. The mean maternal serum magnesium in the test group was significantly higher than in the control group (p = 0.008). The mean neonatal serum magnesium in the test group was also significantly higher compared to the control group (p = 0.008). There were statistically significant differences in serum sodium (p = 0.015), urea (p = 0.043) and creatinine (p = 0.008) levels between the maternal test and control groups. There were significant differences in serum urea (p = 0.007) and chloride (p = 0.017) between the neonatal test and control groups. The calcium and potassium levels were elevated in the test group but not to significant levels. There was a positive correlation between maternal and neonatal serum magnesium levels in both groups stronger in the test group (r = 0.56, p = 0.003) as compared to the control group (r = 0.35, p = 0.087).

Conclusion: Maternally administered magnesium sulphate raises urea and creatinine levels to significant levels in mothers. Calcium levels are also raised while in mothers not receiving magnesium sulphate they were slightly lower. In neonates the urea and chloride levels are elevated to significant levels while the calcium and potassium levels are not significantly elevated. We suggest monitoring of both in the immediate post-partum period.

Keywords: Preeclampsia, eclampsia, magnesium sulphate, neonate, serum urea and electrolytes.


References


Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D (2002). The Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The

Magpie Trial: A randomized placebo-controlled trial. Lancet. 359: 1877–1890.

Bansal (1985). Preeclampsia/eclampsia: a profile from Pumwani Maternity Hospital Kenya. East Afr. Med. J. 62:691-8.

Barton JR, Witlin AG, Sibai BM (1999). Management of mild preeclampsia. Clin. Obstet. Gynecol. 42:455-69.

Chesley LC, Tepper I (1957). Plasma levels of magnesium attained in magnesium sulfate therapy for preeclampsia and eclampsia. Surg. Clin. North Am. 37:35367.

Cooray SD, Edmonds SM, Tong S, Samarasekera SP, Whitehead CL (2011). Characterization of symptoms immediately preceding eclampsia. Obstet. Gynecol. 118: 995-9.

CPMP/PEG/35132/03: Discussion paper on the impact of renal immaturity when investigating medicinal products intended for paediatric use. (2004) European Medicines Agency London, 16 December

Dangman BC, Rosen TS (1977). Magnesium levels in infants of mothers treated with MgSO4 (Abstract #262). Pediatr. Res. 11:415.

Donovan EF, Tsang RC, Steichen JJ, Strub RJ, Chen IW, Chen M.(1980) Neonatal hypermagnesemia: effect on parathyroid hormone and calcium homeostasis. J Pediatr. 96:30510.

Hallak M, Cotton DB (1993). Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat: assessment of amniotic fluid, blood, and brain concentrations. Am. J. Obstet. Gynaecol. 169:427-31

Hyun HS, Choi HS, Kim JK, Ahn SY, Yoo HS, Kim ES, Chang YS, Park WS (2011). Idiopathic severe hypermagnesemia in an extremely low birth weight infant on the first day of life. Korean J. Pediatr. 54:310-2.

Idama T, Lindow S (1998). Magnesium Sulphate: a review of clinical pharmacology applied to obstetrics. Br. J. Obstetr. Gynaecol. 105:260-268.

Iglesias MH, Giesbrecht EM, von Dadelszen P, Magee LA (2011). Postpartum hyperkalemia associated with magnesium sulfate. Hypertens. Pregnancy. 30:481.

Lamm CI, Norton KI, Murphy RJC, Wilkins IA, Rabinowitz JG (1988). Congenital rickets associated with magnesium sulfate infusion for tocolysis. J. Pediatr. 113:107882.

Lipsitz PJ and English IC (1967). Hypermagnesemia in the newborn infant. Pediatrics. 40:856.

Lu JF, Nightingale CH (2000). Magnesium Sulfate in Eclampsia and Pre-Eclampsia: Pharmacokinetic Principles. Clinical Pharmacokinetics. 38:305-314.

MacIntyre I, Boss S, and Troughton VA (1963). Parathyroid hormone and magnesium homeostasis. Nature 198:1058.

Mason BA, Standley CA, Whitty JE, Cotton DB. (1996). Fetal ionized magnesium levels parallel maternal levels during magnesium sulfate therapy for preeclampsia. Am. J. Obstet. Gynecol. 175:213-7.

Martinerie L, Pussard E, Foix-L'hélias L, Petit F, Cosson C, Boileau P, Lombè M (2009). Physiological partial aldosterone resistance in human newborns. Paed. Res. 66;323-328.

McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ (2010). Kidney disease after preeclampsia: a systematic review and meta-analysis. Am. J. Kidney Dis. 55:1026.

Mildenberger E, Versmold HT (2002). Pathogenesis and therapy of non-oliguric hyperkalaemia of the premature infant. Eur. J. Pediatr. 161: 415 – 422.

Nader PJ, Procianoy RS (1996). Hyperkalemia in very low birth weight infants: incidence and associated factors. J. Pediatr. 72:143-150.

Osungbade KO and Ige OK (2011). Public health perspectives of preeclampsia in developing countries: Implication for health system strengthening. J. Pregnancy. Article ID: 481095. http://dx.doi.org/10.1155/2011/481095

Pruett KM, Kirshon B, Cotton DB, Adam K, Doody KJ (1988). The effects of magnesium sulfate therapy on Apgar scores. Am J. Obstet. Gynecol. 159:10478.

Ries A, Kopelman JN, Macri C (2000). Laboratory testing for preeclampsia: result trends and screening recommendations. Mil. Med. 165:546-8.

Savory J, Monif GRG (1971). Serum calcium levels in cord sera of the progeny of mothers treated with magnesium sulfate for toxemia of pregnancy. Am. J. Obstet. Gynecol. 110:5569

Schauberger CW, Pitkin RM (1979). Maternal-perinatal calcium relationships. Obstet. Gynecol. 53:74-6.

Semama DS, Martin-Delgado M, Gouyon JB (2007). Metabolism of potassium in preterm infants. Arch. Pediatr. 14:249-253.

Sibai BM, Anderson GD, McCubbin JH (1982). Eclampsia II. Clinical significance of laboratory findings. Obstet. Gynecol. 59:153-7.

Sibai BM. (2003). Diagnosis and management of gestational hypertension and preeclampsia. Obstet. Gynecol. 102:181-92.

Sibai BM (2005). Diagnosis, prevention, and management of eclampsia. Obstet. Gynecol. 105:402-10.

Wagner LK (2004). Diagnosis and management of preeclampsia. Am. Fam. Physician. 70:2317-24.

Widdowson E.M, Mccance RA (1965). The metabolism of calcium, phosphorus, magnesium and strontium. Pediat. Clin. N. Amer. 12:595.


Full Text: PDF

Refbacks

  • There are currently no refbacks.